Enzo Biochem, Inc. (NYSE:ENZ) tinted gains of +3.34% (+0.13 points) to US$4.02. The volume of 0.15 Million shares climbed down over an trading activity of 188.61 Million shares. EPS ratio determined by looking at last 12 month figures is -0.33. Over the same time span, the stock marked US$7.4 as its best level and the lowest price reached was US$2.32. The corporation has a market cap of US$189.7 Million.
Enzo Biochem, Inc. (NYSE:ENZ)’s earnings per share has been growing at a 13.8 percent rate over the past 5 year when average revenue increase was noted as 2.2 percent. The return on equity ratio or ROE stands at -18.9 percent while most common profitability ratio return on investment (ROI) was -13.5 percent. The company’s institutional ownership is monitored at 69.7 percent. The company’s net profit margin has achieved the current level of -15.9 percent and possesses 39.8 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 2. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Bancolombia S.A. (NYSE:CIB) is worth US$11.12 Billion and has recently risen 3.33% to US$46.5. The latest exchange of 0.28 Million shares is below its average trading activity of 314.58 Million shares. The day began at US$44.61 but the price moved to US$44.61 at one point during the trading and finally capitulating to a session high of US$46.54. The stock tapped a 52-week high of US$51.38 while the mean 12-month price target for the shares is US$45.64.
Currently, the stock carries a price to earnings ratio of 13.85, a price to book ratio of 1.51, and a price to sales ratio of 2.2. For the past 5 years, the company’s revenue has grown 16.9%, while the company’s earnings per share has grown 19.2%. With an institutional ownership near 40.7%, it carries an earnings per share ratio of 3.36.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 5 analysts recommended Holding these shares while 2 recommended sell, according to FactSet data. 2 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 3.5.